PRONTOX——质子治疗减少局部晚期非小细胞肺癌急性正常组织毒性的随机对照试验研究方案
PRONTOX为单中心、前瞻性、随机对照II期临床试验,比较光子与质子放疗(至66 Gy(RBE))联合同步标准化疗在局部晚期NSCLC患者中的效果。患者按1:1分配至光子或质子治疗组,治疗轻度加速,每周6次2 Gy(RBE)。主要终点为放射性食管炎和肺炎(≥II级)从39%降至12%,次要终点包括局部区域和远处失败、总生存及晚期副作用。
要点
- 光子联合同步化疗是局部晚期NSCLC的标准治疗。
- 质子治疗因物理特性可更好保护正常组织,减少放射诱导副作用。
- 试验假设质子治疗将≥II级食管炎和肺炎从39%降至12%。
核心结论
- 研究总体目标是显示质子治疗减少早期和中期放射诱导毒性。
研究设计与样本
- 单中心、前瞻性、随机对照II期临床试验,比较光子与质子放疗至66 Gy(RBE)联合同步标准化疗。
- 局部晚期NSCLC患者按1:1比例分配至光子或质子治疗组。
- 治疗轻度加速,每周6次2 Gy(RBE)。
关键数值与推荐
- 主要终点假设≥II级放射性食管炎和肺炎从39%降至12%。
- 次要终点包括局部区域和远处失败、总生存及晚期副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary radiochemotherapy with photons is the standard treatment for locally advanced-stage non-small cell lung cancer (NSCLC) patients. Acute radiation-induced side effects such as oesophagitis and radiation pneumonitis limit patients' quality of life, and the latter can be potentially life-threatening. Due to its distinct physical characteristics, proton therapy enables better sparing of normal tissues, which is supposed to translate into a reduction of radiation-induced side effects. METHODS/DESIGN: This is a single-centre, prospective, randomised controlled, phase II clinical trial to compare photon to proton radiotherapy up to 66 Gy (RBE) with concomitant standard chemotherapy in patients with locally advanced-stage NSCLC. Patients will be allocated in a 1:1 ratio to photon or proton therapy, and treatment will be delivered slightly accelerated with six fractions of 2 Gy (RBE) per week. DISCUSSION: The overall aim of the study is to show a decrease of early and intermediate radiation-induced toxicity using proton therapy. For the primary endpoint of the study we postulate a decrease of radiation-induced side effects (oesophagitis and pneumonitis grade II or higher) from 39 to 12%. Secondary endpoints are locoregional and distant failure, overall survival and late side effects. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with Identifier NCT02731001 on 1 April 2016.
引用
- Zschaeck S, Simon M, Löck S, et al. PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials. 2016. PMID: 27846903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。